Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Show more
Location: 225 Franklin Street, Boston, MA, 02110, United States | Website: https://ateapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
314.1M
52 Wk Range
$2.46 - $4.14
Previous Close
$3.78
Open
$3.75
Volume
311,695
Day Range
$3.66 - $3.79
Enterprise Value
-115.9M
Cash
425.4M
Avg Qtr Burn
-31.55M
Insider Ownership
11.79%
Institutional Own.
66.86%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C | Phase 3 Data readout | |
AT-527 (Bemnifosbuvir) Details COVID-19, Infectious disease | Failed Discontinued | |
AT-752 Details Infectious disease, Dengue Fever | Failed Discontinued | |
Failed Discontinued |